BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Monday.

Several other brokerages have also recently issued reports on BCRX. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, HC Wainwright reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $8.00.

BioCryst Pharmaceuticals (BCRX) traded up 7.86% during trading on Monday, reaching $4.94. 800,844 shares of the company traded hands. BioCryst Pharmaceuticals has a 12-month low of $3.75 and a 12-month high of $9.25. The firm’s market capitalization is $397.31 million. The firm’s 50 day moving average price is $4.97 and its 200 day moving average price is $6.16.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the previous year, the company earned ($0.22) earnings per share. The firm’s revenue was down 35.4% on a year-over-year basis. Equities research analysts expect that BioCryst Pharmaceuticals will post ($0.74) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “BioCryst Pharmaceuticals, Inc. (BCRX) Lifted to Hold at ValuEngine” was first published by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.watchlistnews.com/biocryst-pharmaceuticals-inc-bcrx-lifted-to-hold-at-valuengine/1528498.html.

Several hedge funds have recently added to or reduced their stakes in BCRX. The Manufacturers Life Insurance Company raised its stake in BioCryst Pharmaceuticals by 6.4% in the second quarter. The Manufacturers Life Insurance Company now owns 63,116 shares of the biotechnology company’s stock valued at $351,000 after buying an additional 3,774 shares during the last quarter. RA Capital Management LLC raised its stake in BioCryst Pharmaceuticals by 47.9% in the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after buying an additional 1,672,447 shares during the last quarter. State Street Corp raised its stake in BioCryst Pharmaceuticals by 72.0% in the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after buying an additional 1,636,909 shares during the last quarter. DAFNA Capital Management LLC raised its stake in BioCryst Pharmaceuticals by 9.2% in the second quarter. DAFNA Capital Management LLC now owns 591,128 shares of the biotechnology company’s stock valued at $3,287,000 after buying an additional 50,000 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $233,000. 86.23% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.